Table 4.
Baseline Demographic and Clinical Characteristics of Randomized Completer Participants of the MGTT; ITT Model, Minnesota, 2009–2014 (n= 937)
| GTE (n= 463) | Placebo (n= 474) | P valuea | |
|---|---|---|---|
| Age at baseline, y | 60.0 (4.9) | 59.7 (5.0) | 0.26 |
| Race | 0.44 | ||
| - White | 453 (97.8%) | 458 (96.6%) | |
| - Asian | 3 (0.7%) | 7 (1.5%) | |
| - Black | 2 (0.4%) | 5 (1.1%) | |
| - Others | 4 (0.9%) | 2 (0.4%) | |
| - Unknown | 1 (0.2%) | 2 (0.4%) | |
| Ethnicity | 0.90 | ||
| - Hispanic | 5 (1.1%) | 4 (0.8%) | |
| - Non-Hispanic | 453 (97.8%) | 464 (97.9%) | |
| - Unknown | 5 (1.1%) | 6 (1.3%) | |
| COMT genotype | 0.32 | ||
| - High | 126 (27.2%) | 122 (25.7%) | |
| - Intermediate | 181 (39.1%) | 208 (43.9%) | |
| - Low | 156 (33.7%) | 144 (30.4%) | |
| Level of education | 0.14 | ||
| - High school or less | 27 (5.8%) | 31 (6.5%) | |
| - Some college | 313 (67.6%) | 287 (60.6%) | |
| - Postgraduate or professional degree | 121 (26.1%) | 152 (32.1%) | |
| - Unknown | 2 (0.4%) | 4 (0.8%) | |
| Family history of breast cancerb | 0.22 | ||
| - No | 332 (71.7%) | 355 (74.9%) | |
| - Yes | 120 (25.9%) | 114 (24.1%) | |
| - Unknown | 11 (2.4%) | 5 (1.1%) | |
| Age at menarche, yc | 13.0 (1.4) | 12.9 (1.4) | 0.78 |
| Parity Status | 0.27 | ||
| - Nulliparous | 108 (23.3%) | 110 (23.2%) | |
| - Parous | 354 (76.5%) | 359 (75.7%) | |
| - Unknown | 1 (0.2%) | 5 (1.1%) | |
| Age at first live birth, yd,e | 27.9 (5.4) | 28.6 (5.4) | 0.07 |
| Breastfeeding, total monthsd,f | 13.3 (17.4) | 13.5 (16.2) | 0.87 |
| Type of menopause | 0.18 | ||
| - Natural | 397 (85.8%) | 409 (86.3%) | |
| - Surgical: bilateral oophorectomy | 35 (7.6%) | 45 (9.5%) | |
| - Surgical: ovarian status unknown | 27 (5.8%) | 15 (3.2%) | |
| - Unknown | 4 (0.9%) | 5 (1.1%) | |
| Age at menopause, yg | 49.0 (5.7) | 49.3 (5.2) | 0.47 |
| Years since menopauseh | 11.1 (7.6) | 10.3 (7.2) | 0.13 |
| Past use of oral contraceptives | 0.85 | ||
| - No | 65 (14.0%) | 70 (14.8%) | |
| - Yes | 395 (85.3%) | 402 (84.8%) | |
| - Unknown | 3 (0.7%) | 2 (0.4%) | |
| Past use of hormone therapy | 0.95 | ||
| - No | 270 (58.3%) | 278 (58.7%) | |
| - Yes | 189 (40.8%) | 191 (40.3%) | |
| - Unknown | 4 (0.9%) | 5 (1.1%) | |
| Height, cm | 163.6 (6.3) | 164.3 (6.1) | 0.10 |
| Weight, kg | 67.3 (10.7) | 67.4 (10.3) | 0.94 |
| BMI, kg/m2 | 25.2 (3.7) | 25.0 (3.7) | 0.52 |
| Waist-to-hip ratio | 0.84i (0.1) | 0.83 (0.1) | 0.21 |
| Use of vitamin supplements | 0.04 | ||
| - No | 42 (9.1%) | 66 (13.9%) | |
| - Yes | 420 (90.7%) | 408 (86.1%) | |
| - Unknown | 1 (0.2%) | 0 (0.0%) | |
| Smoking status | 0.84 | ||
| - Never | 316 (68.3%) | 324 (68.4%) | |
| - Former | 145 (31.3%) | 149 (31.4%) | |
| - Unknown | 2 (0.4%) | 1 (0.2%) | |
| Alcohol drinks/week (drinkers only)j | 3.4 (3.0) | 3.4 (3.0) | 0.81 |
| Self-reported physical activity, MET-h/weekk | 45.7 (54.0) | 51.0 (106.9) | 0.34 |
Abbreviations: BMI, body mass index; COMT, catechol-O-methyltransferase; GTE, green tea extract; ITT, intention-to-treat; MET, metabolic equivalent; MGTT, Minnesota Green Tea Trial.
NOTE: Data presented as the means (SD) for continuous variables and as frequencies (%) for categorical variables.
P value for difference between the GTE-completers with the Placebo-completers.
Only in first degree relatives.
GTE (n): completers= 457; Placebo (n): completers= 460.
Among parous women only.
GTE (n): completers= 354; Placebo (n): completers= 359.
GTE (n): completers= 348; Placebo (n): completers= 353.
GTE (n): completers= 442; Placebo (n): completers= 454.
GTE (n): completers= 440; Placebo (n): completers= 454.
n= 461.
GTE (n): completers= 368; Placebo (n): completers= 396.
GTE (n): completers= 463; Placebo (n): completers= 473.